MedPlus Q1 FY27 Results: Revenue Rises 21.8%, Store Network Expands to 5,476, While Margins Come Under Pressure

What Happened ?

key details

Pharmacy Business Performance:

The pharmacy business remained the primary growth driver during Q1 FY27, supported by continued store expansion, healthy customer demand and wider market penetration. MedPlus strengthened its retail presence while maintaining one of the largest pharmacy networks in India.

Operational Highlights:

• Revenue increased 21.8% YoY to ₹18,796 million.
• Quarterly revenue achieved 99% of the company’s Annual Operating Plan (AOP) target.
• The pharmacy network expanded to 5,476 stores.
• Operations now span 850+ cities and towns across India.
• Growth was driven by both mature stores and new store additions during the quarter. 

Store Expansion:

MedPlus continued executing its aggressive expansion strategy through a combination of company-owned and franchise-operated pharmacies.

Expansion Highlights

• Added 146 net new stores during Q1 FY27.
• Opened 131 new franchise stores, reflecting an asset-light expansion approach.
• Continued strengthening presence across Tier-II, Tier-III and emerging urban markets.
• The expanding store network is expected to improve customer accessibility and support long-term revenue growth.

Margin Performance:

Despite strong revenue growth, profitability was affected by changes in product mix and franchise economics.

Key Developments

• Gross margin declined to 24.5% from 26.1% in Q1 FY26.
• The decline was primarily due to:
  • Lower contribution from higher-margin private label products.
  • Reduced margins from the expanding franchise business.
• Operating EBITDA margin contracted to 3.5% from 4.7% in the previous year.
• EBITDA target achievement reached 81.6% of the Annual Operating Plan due to margin pressure. 

Business Strategy:

MedPlus continues to focus on expanding its pharmacy footprint while improving customer reach through a scalable retail model.

Strategic Priorities

• Accelerate store expansion across underserved markets.
• Increase franchise-led growth to improve capital efficiency.
• Expand private label penetration over the medium term.
• Improve operational efficiency across the retail network.
• Continue strengthening omnichannel healthcare and pharmacy services.

Operational Outlook:

Management highlighted that store expansion remains a key long-term growth driver despite short-term pressure on margins.

Business Outlook

• A larger store network is expected to support sustainable revenue growth.
• Improving the contribution of private label products remains an important lever for future margin expansion.
• Franchise expansion is expected to enhance market penetration while reducing capital requirements.
• Continued execution against the Annual Operating Plan remains a management priority for FY27. 

Market Position:

MedPlus continues to strengthen its position as one of India’s largest organised pharmacy retailers through scale, geographic reach and an expanding omnichannel presence.

Competitive Strengths

• One of India’s largest pharmacy chains with 5,476 stores.
• Presence across 850+ locations provides significant distribution reach.
• Strong brand recognition in organised pharmacy retail.
• Large and expanding retail network supports long-term operating leverage as store maturity improves. 

Note:

• MedPlus delivered another quarter of strong network expansion and healthy revenue growth, reinforcing its leadership in organised pharmacy retail.
• While lower private label contribution and franchise mix weighed on profitability during Q1 FY27, continued store additions, wider geographic coverage and execution of its expansion strategy position the company for sustained long-term growth. 

Risk Analysis

Summary:

• MedPlus delivered robust revenue growth and continued to expand its pharmacy network during Q1 FY27. However, profitability came under pressure due to lower gross margins, driven by an unfavourable product mix and higher contribution from the franchise business. While the company’s long-term expansion strategy remains intact, investors should monitor margin recovery, private label penetration and the profitability of newly added stores.

Key Risks:

• Gross Margin Pressure: Gross margin declined by 160 basis points YoY to 24.5%, primarily due to a lower contribution from higher-margin private label products and reduced margins in the franchise business.
• Profitability Compression: Despite a 21.8% increase in revenue, Operating EBITDA fell 10.6% YoY, while PAT declined 21.7% YoY, indicating that earnings growth is currently lagging revenue growth.
• Private Label Mix Risk: Management attributed a significant portion of the margin decline to a lower sales mix of private label products. Sustained weakness in private label sales could continue to affect profitability.
• Franchise Economics: Rapid franchise expansion supports network growth but currently generates lower gross margins than company-operated stores, creating pressure on overall operating margins.
• New Store Maturity: The addition of 146 stores during the quarter increases future growth potential, but recently opened stores generally require time to reach optimal sales productivity and profitability.
• Execution Risk: Maintaining operational efficiency while expanding beyond 5,400 stores across 850+ cities will require disciplined inventory management, supply chain execution and cost control.
• Competitive Retail Environment: India’s organised pharmacy sector remains highly competitive, with pricing pressure and promotional activity potentially impacting future margins and market share. 

Worst Case:

• If private label penetration remains weak, franchise expansion continues to dilute margins and newly opened stores take longer than expected to achieve profitability, MedPlus could experience continued pressure on Operating EBITDA and earnings despite maintaining healthy revenue growth.

Risk Level: Medium

Company Commentary

Management highlighted that MedPlus maintained strong business momentum during Q1 FY27 through healthy revenue growth and accelerated store expansion, while acknowledging that profitability was affected by temporary margin pressures.

Key management highlights include:

• Revenue increased 21.8% YoY to ₹18,796 million, reflecting continued customer demand and network expansion.
• The company added 146 new stores, including 131 franchise stores, taking the total network to 5,476 pharmacies.
• Gross margin declined mainly because of a lower contribution from private label products and reduced margins in the expanding franchise business.
• Revenue achieved 99% of the Annual Operating Plan target, demonstrating continued execution strength despite a challenging operating environment.
• Management remains focused on expanding the pharmacy network, improving private label contribution, strengthening operational efficiency and driving sustainable long-term growth across India’s organised pharmacy market.